Loading clinical trials...
Loading clinical trials...
Identification of the Immuno Suppressive Characteristics of Glioma Patients by an Integrated Radio-immunological Approach
The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression. During tumor progression, the infiltration of inflammatory leukocytes, especially of myeloid origin, endowed with immunosuppressive function is observed. Aim of this study is to evaluate myeloid cell infiltrate and iron metabolism in tumor-associated macrophages by combining a multimodal MRI imaging technique with immunophenotyping of the tumor microenvironment.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
University Hospital
Florence, Italy
University Hospital
Padua, Italy
Start Date
February 23, 2022
Primary Completion Date
June 30, 2025
Completion Date
December 31, 2026
Last Updated
January 23, 2026
31
ACTUAL participants
Lead Sponsor
Istituto Oncologico Veneto IRCCS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06172595